Drug intelligence / Profile preview

omeprazole + perindopril

Development stage
Unknown
Lead developer
AstraZeneca
Modality
Small Molecules
Administration
Oral
01

Overview

Omeprazole + perindopril is a therapeutic combination consisting of a proton pump inhibitor (PPI) and an angiotensin-converting enzyme (ACE) inhibitor. Omeprazole acts by irreversibly inhibiting the gastric H+/K+-ATPase enzyme system (the proton pump) in the parietal cells of the stomach, effectively suppressing gastric acid secretion. This is utilized in the management of gastroesophageal reflux disease (GERD), peptic ulcers, and for gastric protection. Perindopril is a long-acting ACE inhibitor that is converted into its active metabolite, perindoprilat, which prevents the conversion of angiotensin I to angiotensin II. This results in decreased systemic vascular resistance, lower blood pressure, and reduced afterload, making it a mainstay in the treatment of hypertension, heart failure, and stable coronary artery disease. While not typically available as a single fixed-dose combination pill, these two agents are frequently co-administered in patients with cardiovascular comorbidities who also require acid suppression therapy.

Other names
omeprazole and perindoprilperindopril and omeprazole
02

Targets

ACE (Angiotensin Converting Enzyme)ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on omeprazole + perindopril.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on omeprazole + perindopril.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call